NASDAQ: EPRX
Eupraxia Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their EPRX stock forecasts and price targets.

Forecast return on equity

Is EPRX forecast to generate an efficient return?

Company
-34.89%
Industry
140.91%
Market
90.47%
EPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EPRX forecast to generate an efficient return on assets?

Company
-34.14%
Industry
32.45%
EPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EPRX earnings per share forecast

What is EPRX's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.79
Avg 2 year Forecast
-$0.72
Avg 3 year Forecast
-$0.70

EPRX revenue forecast

What is EPRX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$5.0M
Avg 2 year Forecast
$35.0M
Avg 3 year Forecast
$90.0M

EPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EPRX$3.86N/AN/A
RAPT$1.04$5.67+444.90%Buy
IKT$1.86N/AN/A
NMRA$0.85$6.00+610.06%Hold
KYTX$3.22$12.50+288.20%Strong Buy

Eupraxia Pharmaceuticals Stock Forecast FAQ

What is EPRX's earnings growth forecast for 2025-2027?

(NASDAQ: EPRX) Eupraxia Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Eupraxia Pharmaceuticals's earnings in 2025 is -$26,354,831.On average, 1 Wall Street analyst forecast EPRX's earnings for 2025 to be -$28,156,866, with the lowest EPRX earnings forecast at -$28,156,866, and the highest EPRX earnings forecast at -$28,156,866. On average, 1 Wall Street analyst forecast EPRX's earnings for 2026 to be -$25,661,954, with the lowest EPRX earnings forecast at -$25,661,954, and the highest EPRX earnings forecast at -$25,661,954.

In 2027, EPRX is forecast to generate -$24,949,122 in earnings, with the lowest earnings forecast at -$24,949,122 and the highest earnings forecast at -$24,949,122.

If you're new to stock investing, here's how to buy Eupraxia Pharmaceuticals stock.

What is EPRX's revenue growth forecast for 2027-2029?

(NASDAQ: EPRX) Eupraxia Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Eupraxia Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast EPRX's revenue for 2027 to be $178,208,015, with the lowest EPRX revenue forecast at $178,208,015, and the highest EPRX revenue forecast at $178,208,015. On average, 1 Wall Street analysts forecast EPRX's revenue for 2028 to be $1,247,456,105, with the lowest EPRX revenue forecast at $1,247,456,105, and the highest EPRX revenue forecast at $1,247,456,105.

In 2029, EPRX is forecast to generate $3,207,744,270 in revenue, with the lowest revenue forecast at $3,207,744,270 and the highest revenue forecast at $3,207,744,270.

What is EPRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EPRX) forecast ROA is -34.14%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is EPRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EPRX) Eupraxia Pharmaceuticals's current Earnings Per Share (EPS) is -$0.77. On average, analysts forecast that EPRX's EPS will be -$0.79 for 2025, with the lowest EPS forecast at -$0.79, and the highest EPS forecast at -$0.79. On average, analysts forecast that EPRX's EPS will be -$0.72 for 2026, with the lowest EPS forecast at -$0.72, and the highest EPS forecast at -$0.72. In 2027, EPRX's EPS is forecast to hit -$0.70 (min: -$0.70, max: -$0.70).

What is EPRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EPRX) forecast ROE is -34.89%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.